Last reviewed · How we verify
ONO-7475
At a glance
| Generic name | ONO-7475 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer (PHASE1)
- A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer (PHASE1)
- A Study of ONO-7475 in Patients With Acute Leukemias (PHASE1, PHASE2)
- Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-7475 CI brief — competitive landscape report
- ONO-7475 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI